ACXP
Acurx Pharmaceuticals, Inc. NASDAQ Listed Jun 25, 2021$1.40
-5.74%
vs $1.48
Mkt Cap $6.0M
52w Low $1.31
1.2% of range
52w High $8.34
50d MA $1.52
200d MA $2.68
P/E (TTM)
—
EV/EBITDA
—
P/B
0.4x
Debt/Equity
0.0x
ROE
-151.2%
P/FCF
-0.0x
RSI (14)
47.10
ATR (14)
$0.09
Beta
-1.92
50d MA
$1.52
200d MA
$2.68
Avg Volume
122.0K
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
259 Liberty Avenue · Staten Island, NY 10305 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | BMO | -0.38 | -0.53 | -40.7% | 1.48 | -9.5% | -5.7% | — | — | — | — | — |
| May 12, 2026 | BMO | -0.59 | -0.62 | -5.1% | 2.18 | +0.0% | -6.0% | -2.9% | -2.5% | -1.0% | -6.2% | — |
| Mar 13, 2026 | BMO | -1.01 | -0.31 | +69.3% | 3.88 | +0.8% | +24.0% | +1.5% | +6.8% | +27.3% | -15.5% | — |
| Nov 12, 2025 | BMO | -1.61 | -1.23 | +23.6% | 4.98 | +0.4% | -4.8% | -3.2% | -8.1% | +2.8% | -7.8% | — |
| Aug 11, 2025 | BMO | -2.00 | -1.89 | +5.5% | 4.48 | -4.0% | -1.1% | +6.5% | +3.0% | +5.1% | +0.8% | — |
| May 12, 2025 | BMO | -0.15 | -2.20 | -1366.7% | 7.91 | -1.4% | -3.9% | -3.3% | +1.5% | +3.8% | +4.7% | — |
| Mar 17, 2025 | BMO | -0.18 | -0.16 | +11.1% | 9.46 | +1.5% | -14.2% | +3.1% | +0.1% | +1.1% | +1.8% | — |
| Nov 12, 2024 | BMO | -0.23 | -0.17 | +26.1% | 37.00 | +2.2% | -1.6% | -2.7% | -2.8% | -1.2% | -1.8% | — |
| Aug 9, 2024 | BMO | -0.28 | -0.26 | +7.1% | 37.60 | +1.1% | -0.5% | +1.6% | +0.0% | +7.4% | -1.5% | — |
| May 14, 2024 | BMO | -0.24 | -0.28 | -16.7% | 41.80 | +2.4% | +7.7% | -4.0% | +4.2% | -0.9% | +25.1% | — |
| Mar 15, 2024 | BMO | -0.26 | -0.38 | -46.2% | 54.40 | -1.8% | -4.8% | -18.5% | +0.0% | -2.4% | -5.8% | — |
| Nov 13, 2023 | BMO | -0.28 | -0.24 | +14.3% | 70.00 | -0.9% | -2.9% | +1.2% | +5.2% | +2.2% | -2.2% | — |
| Aug 14, 2023 | AMC | -0.29 | -0.28 | +3.4% | 33.40 | +1.8% | -4.2% | +8.1% | +9.2% | -1.6% | +7.0% | — |
| May 12, 2023 | AMC | -0.34 | -0.25 | +26.5% | 60.60 | +2.0% | +11.9% | -7.4% | +0.0% | -4.1% | +0.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.28 | $4.18 | -2.3% | +0.2% | +7.2% | -0.9% | -0.2% | -5.9% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.48 | $4.30 | -4.0% | -1.1% | +6.5% | +3.0% | +5.1% | +0.8% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.12 | $8.06 | -0.7% | +3.1% | +0.1% | +1.1% | +1.8% | -1.3% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.16 | $15.60 | -3.5% | -13.4% | -0.1% | +3.0% | +9.3% | +12.2% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.02 | $15.88 | +5.7% | +7.6% | -13.4% | -0.1% | +3.0% | +9.3% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.70 | $17.80 | +0.6% | +5.0% | -5.0% | +0.5% | -3.6% | -3.5% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.40 | $37.00 | +1.6% | -2.7% | -2.8% | -1.2% | -1.8% | -16.8% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.60 | $38.00 | +1.1% | -0.5% | +1.6% | +0.0% | +7.4% | -1.5% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.00 | $45.40 | +0.9% | -4.0% | +4.2% | -0.9% | +25.1% | -8.6% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $51.80 | $47.80 | -7.7% | -18.5% | +0.0% | -2.4% | -5.8% | +7.7% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.60 | $63.60 | +1.6% | -6.7% | -1.7% | +3.1% | -1.0% | +2.0% |
| Dec 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.20 | $69.40 | +3.3% | +4.2% | -0.9% | +0.3% | +0.6% | +2.6% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $68.00 | $67.80 | -0.3% | +1.2% | +5.2% | +2.2% | -2.2% | +2.8% |
| Sep 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.00 | $36.20 | +3.4% | -4.6% | +3.6% | +2.3% | -4.0% | +0.6% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.40 | $34.00 | +1.8% | -4.2% | +8.1% | +9.2% | -1.6% | +7.0% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $60.60 | $61.80 | +2.0% | +11.9% | -7.4% | +0.0% | -4.1% | +0.7% |
| Apr 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $66.40 | $69.40 | +4.5% | +1.2% | -9.2% | -6.2% | +3.5% | +2.7% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.20 | $65.00 | -3.3% | -6.5% | -2.5% | +2.6% | +2.2% | +3.1% |
| Jan 10 | Alliance Global Partners | Maintains | Buy → Buy | — | $85.00 | $88.20 | +3.8% | -3.5% | +1.2% | +1.9% | +0.5% | -5.9% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $76.60 | $78.40 | +2.3% | -1.6% | +0.8% | +1.3% | -2.1% | +4.2% |
| Oct 20 | Alliance Global Partners | Maintains | Buy → Buy | — | $60.20 | $67.80 | +12.6% | -0.3% | +1.7% | -1.6% | +7.0% | -4.0% |
| Nov 29 | Maxim Group | Maintains | Buy → Buy | — | $97.80 | $100.80 | +3.1% | +3.5% | -5.1% | -9.4% | -3.0% | -1.7% |
No insider trades available.
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
ACXP completed a registered offering of shares and pre-funded warrants, with a lock-up period restricting insider sales, potentially diluting current shareholders but providing near-term capital for operations.
Apr 16
8-K · 5.02
!!! Very High
Acurx Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Acurx Pharmaceuticals reduced non-employee director cash compensation by 10%, suggesting cost-containment measures that may indicate financial constraints or restructuring efforts.
Mar 9
Institutional (13F) — Top 6
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 13,000 | $32K | Added | Dec 2025 |
| 2 | Jane Street Group, Llc | 10,743 | $27K | New | Dec 2025 |
| 3 | Ubs Group Ag | 6,312 | $23K | Added | Mar 2026 |
| 4 | Wells Fargo & Company/mn | 2,300 | $9K | New | Mar 2026 |
| 5 | Western Wealth Management, Llc | 1,325 | $5K | New | Mar 2026 |
| 6 | Barclays Plc | 380 | $1K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 11,494 | $17K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 2,978 | $6K | May 2026 |
| 3 | Fidelity Total Market Index Fund | 1,001 | $2K | May 2026 |
| 4 | Fidelity Nasdaq Composite Index Fund | 146 | $220 | Feb 2026 |
Valuation
Market Cap
$6.0M
Enterprise Value
-$7.55B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.01x
P/B
0.40x
P/S
—
P/FCF
-0.00x
EV/EBITDA
—
Shares Out
1.5M
Financials (TTM)
Revenue
$0
Net Income
-$7.5M
EBITDA
-$7.6M
Free Cash Flow
-$6.79B
Op Cash Flow
-$6.79B
EPS Basic
$-5.32
EPS Diluted
$-3.55
EPS Forward
$-2.16
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$7.7M
Total Liab.
$2.4M
Total Equity
$5.3M
Cash
$7.56B
LT Debt
$0
Book Value/Sh
$3.51
Debt/Equity
0.00x
Current Ratio
3.18
Quick Ratio
3.18
Returns & Growth
ROE
-151.2%
ROA
-103.6%
ROIC
-153.6%
Rev Growth YoY
+0.0%
EPS Growth YoY
+69.8%
Price Returns
2W
-2.8%
1M
-20.3%
3M
-27.3%
6M
-29.2%
12M
-72.7%
Technicals
52W High
$8.34
52W Low
$1.31
50d MA
$1.52
200d MA
$2.68
RSI (14)
47.10
ATR (14)
$0.09
Beta
-1.92
Avg Volume
122K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 10:46am
· Source: financialmodelingprep.com